港股異動 | 康哲藥業(00867.HK)盤初急升 大漲8%創一年新高
格隆匯10月25日丨康哲藥業(00867.HK)盤初股價急升,現漲7.95%,報11.14港元創一年新高,暫成交3743萬港元,最新總市值276.3億港元。

康哲藥業是中國領先的藥品營銷推廣企業。日前輝立證券報告稱,預測公司FY19/FY20/FY21年營業收入同比增長10.12%/5.36%/6.95%,給予“增持”評級。金利豐證券則稱,公司股價整固後有望再上。
此前,公司上半年業績超預期,短期內帶量採購對業績影響的預期明顯改善,中長期公司引進產品儲備豐富、銷售渠道成熟可支撐穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.